Literature DB >> 35834026

Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice.

Giandomenico Roviello1, Martina Catalano2, Carlotta Ottanelli2, Roberta Giorgione2, Virginia Rossi3, Elisabetta Gambale3, Chiara Casadei4, Ugo De Giorgi4, Lorenzo Antonuzzo3,5.   

Abstract

The treatment landscape for metastatic castration-resistant prostate cancer has evolved extremely in recent years and several drug classes are now available. Nonetheless, the lack of validated predictive biomarkers makes therapeutic choice and the best sequential approach difficult. The location of the metastatic site could be a valid criterion for choosing among the treatment options available. Although bone remains the most frequent metastatic site and a possible target for many drugs, recent data suggest a profound shift in the disease spectrum with visceral metastases increasing incidence. This review describes the presently available and ongoing therapies for patients with CRPC and bone metastases, focusing on the role of bone metastases as a possible driver for selecting therapies in these patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  177Lu-PSMA-617; Androgen receptor signaling inhibitors; Bone metastases; Chemotherapy; Metastatic castration-resistant prostate cancer; PARP inhibitors; Sipuleucel-T; radium223

Mesh：

Substances：

Year:  2022        PMID： 35834026     DOI： 10.1007/s12032-022-01739-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.738


  44 in total

1.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Authors:  Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

2.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

3.  Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.

Authors:  N Sathiakumar; E Delzell; M A Morrisey; C Falkson; M Yong; V Chia; J Blackburn; T Arora; M L Kilgore
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-03-15       Impact factor: 5.554

4.  Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.

Authors:  Giorgio Gandaglia; Pierre I Karakiewicz; Alberto Briganti; Niccolò Maria Passoni; Jonas Schiffmann; Vincent Trudeau; Markus Graefen; Francesco Montorsi; Maxine Sun
Journal:  Eur Urol       Date:  2014-08-06       Impact factor: 20.096

5.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

6.  Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.

Authors:  Stephanie M Doctor; Che-Kai Tsao; James H Godbold; Matthew D Galsky; William K Oh
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

7.  Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

Authors:  E J Small; C S Higano; P W Kantoff; J B Whitmore; M W Frohlich; D P Petrylak
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-06-24       Impact factor: 5.554

Review 8.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

9.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096

10.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.